Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585713 · ClinicalTrials.gov registry record · Phase 3
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
A Phase 3 study of Malignant Neoplasm and Pulmonary Embolism, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 18
- Study locations
NCT02585713: Completed Phase 3 study of Malignant Neoplasm and Pulmonary Embolism, sponsored by Academic and Community Cancer Research United.
NCT02585713 is a Phase 3 study of Malignant Neoplasm and Pulmonary Embolism that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 300 participants, below the 508-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (41% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02585713, a Phase 3 study of Malignant Neoplasm and Pulmonary Embolism, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 18
- Study locations
Study Summary
This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE
Primary Outcome
The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Apixaban
- DRUG Dalteparin
Study Locations (18)
Minnesota
- Mayo Clinic - Rochester
- Coborn Cancer Center at Saint Cloud Hospital - Saint Cloud
- Metro Minnesota Community Oncology Research Consortium - Saint Louis Park
Illinois
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Illinois CancerCare-Peoria - Peoria
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
- Siouxland Regional Cancer Center - Sioux City
Ohio
- Columbus NCI Community Oncology Research Program - Columbus
- Toledo Clinic Cancer Centers-Toledo - Toledo
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Kansas
- Cancer Center of Kansas - Wichita - Wichita
Michigan
- Cancer Research Consortium of West Michigan NCORP - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2015-11-20 |
| Est. Completion | 2019-12-24 |
| Phase | Phase 3 |
What the finished NCT02585713 record still lists
NCT02585713 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 508-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (41% lower).
The record links to 10 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT02585713 lists 18 locations in 13 states (Minnesota, Illinois, Iowa).
Frequently Asked Questions
What is clinical trial NCT02585713 about?
NCT02585713 is a clinical study titled "Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism". This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the blood...
What is the current status of trial NCT02585713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2015-11-20. Estimated completion is 2019-12-24.
What conditions does trial NCT02585713 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Pulmonary Embolism, Deep Vein Thrombosis, Metastatic Malignant Neoplasm, Cerebral Vein Thrombosis.
What interventions are being tested in trial NCT02585713?
The interventions under investigation include: Questionnaire Administration (OTHER), Apixaban (DRUG), Dalteparin (DRUG).
Who is sponsoring clinical trial NCT02585713?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02585713 being conducted?
This trial has 18 study locations across Arizona, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02585713's enrollment target sits among peer trials
300 16th of 59 higher than 44 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant
COMPLETED · Phase 3
-
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
COMPLETED · Phase 3
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI